

Supporting Information for

ORIGINAL ARTICLE

Co-delivery of nigericin and decitabine using hexahistidine-metal nanocarriers for pyroptosis-induced immunotherapeutics

Qiang Niu^{a,†}, Yu Liu^{b,†}, Yujing Zheng^{b,†}, Ziwei Tang^a, Yuna Qian^{b,c}, Ruogu Qi^{d,*}, Jianliang Shen^{b,c,*}, Ping Zhao^{a,*}

^a*School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China*

^b*State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology and Optometry, School of Biomedical Engineering, Wenzhou Medical University, Wenzhou 325027, China*

^c*Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325001, China*

^d*School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing 210023, China*

Received 14 August 2022; received in revised form 10 October 2022; accepted 21 October 2022

[†]These authors made equal contributions to this work.

*Corresponding authors.

E-mail addresses: rqi@njucm.edu.cn (Ruogu Qi), shenjl@wiucas.ac.cn (Jianliang Shen), pingzhao@gdpu.edu.cn (Ping Zhao).

Fig. S1 Binding conformation and binding forces between Nig/His₆ and DAC/His₆P3

Fig. S2 Dilution stability analysis and drug release of (Nig+DAC)@HmAP3

Fig. S3 Fluorescence images of MB49 cells incubated with Cy5.....P4

Fig. S4 Cell viability of MB49 cells treated by HmAP4

Fig. S5 MB49 tumor growth curves of each mouse in different treat groups.....P5

Fig. S6 Body weight of MB49 tumor-bearing mice after different treatments.....P5

Fig. S7 4T1 tumor growth curves of each mouse in different treatment groups..... P6

Fig. S8 Body weight of 4T1 tumor-bearing mice after different treatments.....P6

Fig. S9 The gating strategy to sort macrophage (F4/80+) from 4T1 tumor-bearing mice presented
in Fig. 7D.P7




Figure S1 The most stable binding conformation between Nig/His₆ (A) and DAC/His₆ (B). The binding forces between Nig/His₆ (C) and DAC/His₆ (D).

.....Hydrogen bond,Van der Waals, Pi-Alkyl, Pi-Sigma.




Figure S2 (A) Dilution stability analysis of (Nig+DAC)@HmA in bovine serum albumin (BSA) and fetal bovine serum (FBS) buffer at room temperature. (B) Release of drug from (Nig+DAC)@HmA nanoparticles in PBS with pH 5.0 and

7.2.




Figure S3 Representative fluorescence images of MB49 cells incubated with Cy5 at different time points, scale bar = 20 μm .




Figure S4 Cell viability of MB49 cells was treated by HmA with different concentrations. Data are shown as mean \pm SD ($n = 3$).




Figure S5 MB49 tumor growth curves of each mouse in different treatment groups.




Figure S6 Body weight of MB49 tumor-bearing mice after different treatments.

Data are shown as mean \pm SD ($n = 4$).




Figure S7 4T1 tumor growth curves of each mouse in different treatment groups.




Figure S8. Body weight of 4T1 tumor-bearing mice after different treatments.

Data are shown as mean \pm SD ($n = 5$).




Figure S9 The gating strategy to sort macrophage (F4/80⁺) from 4T1 tumor-bearing mice presented in Fig. 7D.